Related references
Note: Only part of the references are listed.Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer
Jane L. Meisel et al.
CLINICAL BREAST CANCER (2020)
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Aidan C. Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Anqi Li et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Applying the New Guidelines of HER2 Testing in Breast Cancer
Huina Zhang et al.
CURRENT ONCOLOGY REPORTS (2020)
A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
Xiaoling Wang et al.
MODERN PATHOLOGY (2020)
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
J. Veeraraghavan et al.
ANNALS OF ONCOLOGY (2019)
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel-Whittemore et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
被撤回的出版物: Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE (Retracted article. See vol. 39, pg. 95, 2021)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
Andrew Dodson et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2018)
'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study
Morgan Ballard et al.
MODERN PATHOLOGY (2017)
The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
Wei Zhang et al.
Analytical Cellular Pathology (2017)
Neoadjuvant Therapy for HER2-positive Breast Cancer
Rachel Wuerstlein et al.
REVIEWS ON RECENT CLINICAL TRIALS (2017)
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
Michael F. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab A Secondary Analysis of the HERA Trial
Sherene Loi et al.
JAMA ONCOLOGY (2016)
Updated UK Recommendations for HER2 assessment in breast cancer
Emad A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
Edith A. Perez et al.
BREAST CANCER RESEARCH (2015)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
F. Montemurro et al.
ANNALS OF ONCOLOGY (2013)
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
P. Sanchez-Rovira et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HER-2 testing in breast cancer using parallel tissue-based methods
H Yaziji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Updated recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/NEU-overexpressing metastatic breast cancer
M Sawaki et al.
TUMORI JOURNAL (2004)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
When is a tumor marker ready for prime time?: A case study of c-erbB-2 as a predictive factor in breast cancer
H Yamauchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2000)
Share Paper
